Looking for a stock that might be in a good position to beat earnings at its next report? Consider Myriad Genetics Inc. (MYGN), a firm in the Drugs industry, which could be a great candidate for another beat. This company has seen a nice …
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MYGN at https://www.zacks.com/ap/MYGN
Myriad Genetics would be listed on the New York Stock Exchange under the ticker symbol “MGX”, and Myriad Pharmaceuticals will be listed on Nasdaq under the company’s current ticker symbol “MYGN.” Myriad has retained J.P. …
Investors found another reason to bid up shares of Myriad Genetics Inc. /quotes/zigman/58124 /quotes/nls/mygn MYGN, which is sole owner of ... hitting a fresh 52-week high. The stock surged last week on third-quarter results that …
GILEAD SCIENCES, INC. (NASDAQ:GILD), FRESH DEL MONTE PRODUCE INC (NYSE:FDP), MYRIAD GENETICS …
Inc. MYGN, each sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. PetMed has a long-term expected earnings growth rate of 10%. The stock has surged roughly 77.9% over a year. …
Inc. MYGN, each sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. PetMed has a long-term expected earnings growth rate of 10%. The stock has rallied roughly 83.9% over a year. …
Salt Lake City, Utah headquartered Myriad Genetics Inc.'s stock finished Wednesday's session 1.97% higher at $33.70. …
Myriad Genetics (NASDAQ:MYGN) traded in a range yesterday that spanned from a low of $37.30 to a high of $39.64. Yesterday, the shares fell 8.0%, which took the trading range below the 3-day low of $40.21 on volume of 993,000 …